Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2026)

Corcept Therapeutics has reported Other Non-Current Liabilities for 9 years, with the latest figure at $15.5 million in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 1.21% year-over-year to $15.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.5 million (down 1.21% YoY) and the FY2025 annual result came in at $15.2 million, up 7.75% from the prior year.
• Other Non-Current Liabilities climbed to $15.5 million in Q2 2026 per CORT's latest filing, from $15.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $15.7 million in Q2 2025 and troughed at $2.5 million in Q1 2022.
• A 5-year average of $11.3 million and a median of $11.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities jumped 2124.21% in 2022, then decreased 1.21% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $9.1 million in 2022, then rose by 13.3% to $10.3 million in 2023, then jumped by 36.64% to $14.1 million in 2024, then climbed by 7.75% to $15.2 million in 2025, then rose by 2.06% to $15.5 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $15.5 million, $15.3 million, and $15.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.